The journal of the Royal College of Physicians of EdinburghHumansAntibodiesMonoclonalHumanizedFemale
Tocilizumab vs bevacizumab in critically ill COVID-19 patients: Registry-based prospective study.
Yatendra Kumar Gupta, Raghubir S Khedar, Gulam Mateen Parihar, Anil Kumar Sharma, Pramod Sarwa, Rajeev Gupta
Published: 202510.1177/14782715251394935
Abstract
BACKGROUND: Tocilizumab, an interleukin-6 (IL-6) inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, have been used in critically ill COVID-19 patients for cytokine storm. We performed a registry-based prospective study…
Preview only. Read the full abstract at the source